Radioimmunotherapy and apoptotic induction on Ck19-overexpressing human cervical carcinoma cells with Re-188-mAbCx-99

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2719-2728

  Chang, Chih Hsien ^a,b   Tsai, Lai Chen ^c   Chen, Shui Tein ^d   Yuan, Chiou Chung ^c   Hung, Mei Whey ^c   Hsieh, Bor Tsung ^e   Chao, Pei Ling ^c   Tsai, Tung Hu ^f   Lee, Te Wei ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^e CHUNGTAI INST HLTH SCI TECHNOL   (Taiwan)

^f NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

Apoptosis; Cervical carcinoma; Ck19; Radioimmunotherapy; Rhenium 188

Indexed keywords

CASPASE 8; CYTOKERATIN 19; DNA FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CX 99; PROTEIN BCL X; PROTEIN MCL 1; PROTEIN P21; PROTEIN P53; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL LYSATE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CARCINOMA; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOREACTIVITY; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; UTERINE CERVIX CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HELA CELLS; HUMANS; IMMUNOTOXINS; KERATINS; NUCLEOSOMES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-JUN; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RHENIUM; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 22944449353     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Taylor CR and Cote RJ: Immunohistochemical markers of prognostic value in surgical pathology. Histol Histopathol 12: 1039-1055, 1997.
2. Busmanis I: Biomarkers in carcinoma of the cervix: emphasis on tissue-related factors and their potential prognostic factors. Ann Acad Med Singapore 27: 671-675, 1998.
3. Keating JT, Ince T and Crum CP: Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 8: 83-92, 2001.
4. Pras E, Willemse PH, Canrinus AA, de Bruijn HW, Sluiter WJ, ten Hoor KA, Aalders JG, Szabo BG and de Vries EG: Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int J Radiat Oncol Biol Phys 52: 23-32, 2002.
5. Yazigi R, Castillo R, Aliste G, Garrido J, Opazo A, Prado S, Navarro C, Altieri E and Del Campo G: Cyfra 21-1 marker in carcinoma of the cervix. Int J Gynecol Cancer 10: 203-206, 2000.
6. Bichat F, Mouawad R, Solis-Recendez G, Khayat D and Bastian G: Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line. Anticancer Res 17: 3393-3401, 1997.
7. Yuan CC, Huang HC, Tsai LC, Ng HT and Huang TS: Cytokeratin-19 associated with apoptosis and chemosensitivity in human cervical cancer cells. Apoptosis 2: 101-105, 1997.
8. Szturmowicz M, Sakowicz A, Wiatr E, Zych J, Zaleska J, Rudzinski P and Rowinska-Zakrzewska E: Evaluation of the value of determining levels of cytokeratin-19 fragments for diagnosis of lung cancer. Pneumonol Alergol Pol 63: 609-614, 1995.
9. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T and Suzuki T: CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 79: 1647-1655, 1997.
10. Yuan CC, Huang TS, Ng HT, Liu RS, Hung MW and Tsai LC: Elevated cytokeratin-19 expression associated with apoptotic resistance and malignant progression of human cervical carcinoma. Apoptosis. 3: 161-169, 1998.
11. Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck A, Harsdorf SV, Glatting G, Grimminger W, Karakas T, Munzert G, Dohner H, Bergmann L and Reske SN: Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 98: 565-572, 2001.
12. 131I-labelled OC125 F(ab')2 on human epithelial ovarian cancer cell lines. Radiother Oncol 23: 150-159, 1992.
13. Tsai LC, Lin JK, Han SH and Chen HM: Suppression of the growth of human colorectal carcinoma cells (LS174T) by radiolabeled monoclonal antibody (131I-MAbC27) in tissue culture and nude mice. Dis Colon Rectum 31: 781-785, 1988.
14. 111In-labeled monoclonal antibody MAb Cx-99. Int J Gynaecol Obstet 49 Suppl: S33-38, 1995.
15. Yuan CC, Tsai LC, Shyong WY, Wang PH, Lee TW, Chang CT and Ng HT: Radioimmunodetection of cervical carcinoma xenografts with (111)In-labeled MAb Cx-99 detected by a hand-held gamma detector. Eur J Gynaecol Oncol 23: 178-182, 2002.
16. Friesen C, Lubatschofski A, Kotzerke J, Buchmann I, Reske SN and Debatin KM: Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging 30: 1251-1261, 2003.
17. Hsieh BT, Callahan AP, Beets AL, Ting G and Knapp FF, Jr.: Ascorbic acid/saline eluent increases 188Re yields after "Wet" storage of 188W/188Re generators. Appl Radiat Isot 47: 23-26, 1996.
18. l88Re generator. Appl Radiat Isot 45: 1123-1128, 1994.
19. Yuan CC, Tsai LC, Hsu SC, Ng HT, Tsai SJ, Chen HM, Hung MW, Ho CK, Ho DM and Gill TJ 3rd: Production and characterisation of a monoclonal antibody (Cx-99) against cervical carcinoma. Br J Cancer 65: 201-207, 1992.
20. Griffiths GL, Goldenberg DM, Knapp FF Jr, Callahan AP, Chang CH and Hansen HJ: Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. Cancer Res 57: 4594-4602, 1991.
21. Tsai LC, Hung MW, Chang GG and Chang TC: Apoptosis induced by the sodium butyrate in human gastric cancer TMK-1 cells. Anticancer Res 20: 2441-2448, 2000.
22. Bonfrer JM, Gaarenstroom KN, Kenter GG, Korse CM, Hart AA, Gallee MP, Helmerhorst TJ and Kenemans P: Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol Oncol 55: 371-375, 1994.
23. Vidrich A, Gilmartin ME, Zimmerman J and Freedberg IM: Glycokerations - potential extracellular components of the intracellular cytokeratin. J Invest Dermatol 80: 340, 1983.
24. Zimmerman J, Vidrich A, Gilmartin ME and Freedberg IM: An extracellular subset of ME 180 keratins. J Cell Biol 95: 237a (abstract), 1982.
25. Hembrough TA, Vasudevan J, Allietta MM, Glass WF 2nd and Gonias SL: A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. J Cell Sci 108 (Pt 3): 1071-1082, 1995.
26. Godfroid E, Geuskens M, Dupressoir T, Parent I and Szpirer C: Cytokeratins are exposed on the outer surface of established human mammary carcinoma cells. J Cell Sci 99 (Pt 3): 595-607, 1991.
27. Donald PJ, Cardiff RD, He DE and Kendall K: Monoclonal antibody-porphyrin conjugate for head and neck cancer: the possible magic bullet. Otolaryngol Head Neck Surg 105: 781-787, 1991.
28. Ditzel HJ, Garrigues U, Andersen CB, Larsen MK, Garrigues HJ, Svejgaard A, Hellstrom I, Hellstrom KE and Jensenius JC: Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment. Proc Natl Acad Sci USA 94: 8110-8115, 1997.
29. Joza N, Kroemer G and Penninger JM: Genetic analysis of the mammalian cell death machinery. Trends Genet 18: 142-149, 2002.
30. Bristow RG, Benchimol S and Hill RP: The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 40: 197-223, 1996.
31. Meyn RE, Stephens LC and Milas L: Programmed cell death and radioresistance. Cancer Metastasis Rev 75: 119-131, 1996.
32. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S and DeNardo GL: Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62: 4263-4272, 2002.